Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Technology Scientific & Technical Instruments
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > Us2.ai !🤔👀 Ventripoint integrated into Ascend's Gen3Echo🚀
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(46)
•••
Comment by jopatcloon Jan 22, 2025 10:27am
31 Views
Post# 36415050

RE:Us2.ai !🤔👀 Ventripoint integrated into Ascend's Gen3Echo🚀

RE:Us2.ai !🤔👀 Ventripoint integrated into Ascend's Gen3Echo🚀Interesting How can AI enhance disease detection on ultrasound? Explore cutting-edge advancements in medical imaging and analysis. Ligence will explain how their echo analysis and reporting software boosts workflow efficiency, while Us2.ai delves into the significance of strain analysis and the future of echo reimbursements in driving AI adoption. https://info.blackfordanalysis.com/webinars/how-ai-enhances-disease-detection-on-ultrasound?utm_campaign=RSNA24&utm_content=322217221&utm_medium=social&utm_source=linkedin&hss_channel=lcp-816117

An honor to speak at the Blackford AI Theater on behalf of Us2.ai, discussing the workflow challenges of echocardiography and the role AI can play.
Next up on the RSNA AI Theater Panel series, we explore how AI can enhance disease detection on ultrasound.

Watch now to see what industry leaders Dovydas Matuliauskas, Ligence's Co-Founder & Business Development, Jeffrey Ronald, See-Mode Technologies' Head of Global Sales and Seth Koeppel, Us2.ai's Business Development have to say about boosting workflow efficiency, the future of echo reimbursements and the value AI brings to clinicians. https://hubs.la/Q032_pFv0

Innovation MedicalImaging HealthcareAI Partnership

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities